Cognition TherapeuticsCGTX
CGTX
About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Employees: 25
0
Funds holding %
of 7,359 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
290% more capital invested
Capital invested by funds: $1.99M [Q3] → $7.76M (+$5.76M) [Q4]
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
16.02% more ownership
Funds ownership: 10.6% [Q3] → 26.62% (+16.02%) [Q4]
10% more funds holding
Funds holding: 40 [Q3] → 44 (+4) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1.50
250%
upside
Avg. target
$6.17
1,339%
upside
High target
$11
2,466%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Daniil Gataulin 18% 1-year accuracy 7 / 38 met price target | 2,467%upside $11 | Buy Maintained | 26 Feb 2025 |
B. Riley Securities Mayank Mamtani 20% 1-year accuracy 4 / 20 met price target | 250%upside $1.50 | Buy Upgraded | 19 Dec 2024 |
HC Wainwright & Co. Raghuram Selvaraju 34% 1-year accuracy 115 / 340 met price target | 1,300%upside $6 | Buy Maintained | 19 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD
Collaborators at the University of Southampton, UK and Cognition Scientists Show Rescue of Function in a Cell Model of Dry AMD Collaborators at the University of Southampton, UK and Cognition Scientists Show Rescue of Function in a Cell Model of Dry AMD
Neutral
GlobeNewsWire
1 week ago
Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit
PITTSBURGH, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced that Mary Hamby, PhD will be co-hosting a precision medicine workshop at the Hanson Wade Neuroimmunology Drug Development Summit. The workshop will review methods of screening participants for clinical trials to ensure that the patients selected are most likely to benefit from treatment.
Neutral
GlobeNewsWire
1 month ago
Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC
– Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB –
Neutral
GlobeNewsWire
1 month ago
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences
PURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that CEO Lisa Ricciardi will be participating at upcoming conferences taking place during the week of the JP Morgan Healthcare Conference 2025.
Positive
Benzinga
2 months ago
Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?
Cognition Therapeutics, Inc. CGTX revealed positive results from the exploratory Phase 2 SHIMMER study demonstrating that CT1812 produced strong therapeutic responses across behavioral, functional, cognitive and movement measures in patients with dementia with Lewy bodies (DLB).
Neutral
GlobeNewsWire
2 months ago
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) - - Cognition Therapeutics and Dr. Galvin, a Principal Investigator, Will Host a Conference Call at 8am ET on December 18 to Review the Topline Data - PURCHASE, N.Y., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced topline results from the exploratory Phase 2 ‘SHIMMER' study demonstrating CT1812 produced strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with dementia with Lewy bodies (DLB).
Positive
Zacks Investment Research
3 months ago
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Cognition Therapeutics (CGTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Neutral
GlobeNewsWire
3 months ago
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies
– Topline results in second dementia indication expected to be reported in December 2024 – PURCHASE, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the last patient has completed their final clinic visit in the Phase 2 SHIMMER study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB).
Neutral
GlobeNewsWire
3 months ago
Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population
- Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer's Disease Biology -
Neutral
GlobeNewsWire
3 months ago
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
- CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD -
Charts implemented using Lightweight Charts™